Stanford Pioneers 4DMedical’s CT:VQ™ Rollout as AstraZeneca Partnership Expands in Brazil

Key Highlights:

• Stanford University becomes the first U.S. Academic Medical Centre to adopt 4DMedical’s CT:VQ™ following FDA clearance.
• Partnership with AstraZeneca expands Brazil’s Lung Health Screening Program to five new hospitals, covering 38,000 CT scans annually.
• CEO Andreas Fouras calls the developments a “powerful validation” of 4DMedical’s commercial strategy.
  
   

4DMedical Ltd (ASX:4DX) has hit two major global milestones this week, marking a transformative step in the company’s path to commercial scale. Less than two months after securing U.S. FDA clearance, Stanford University has become the first Academic Medical Centre (AMC) in the United States to adopt its CT:VQ™ respiratory imaging platform under a commercial contract.

At the same time, pharmaceutical giant AstraZeneca is expanding its collaboration with 4DMedical in Brazil, rolling out the Lung Health Screening Program to five additional hospitals—together handling an estimated 38,000 CT scans annually.

Stanford Leads Commercial Rollout in the U.S.

Stanford Medicine’s 3D Quantitative Imaging Laboratory (3DQ Lab), one of the world’s foremost centers for imaging innovation, will spearhead the commercial use of CT:VQ™—a system designed to redefine cardiothoracic imaging.

This marks a significant validation of 4DMedical’s approach to commercialisation, with the university becoming the first major academic institution to integrate the CT:VQ™ platform into live clinical workflows.

The agreement builds upon Stanford’s existing relationship with 4DMedical, which includes up to 20,000 annual CT scan analyses across the company’s imaging suite—CT LVAS™ and IQ-UIP™ among them.

The introduction of CT:VQ™ on a pay-per-scan model opens reimbursement pathways and accelerates real-world adoption. By delivering high-resolution, contrast-free imaging that integrates seamlessly into existing hospital workflows, CT:VQ™ positions itself as a next-generation alternative to nuclear medicine VQ scans.

Stanford’s move also marks the start of 4DMedical’s Key Opinion Leader (KOL) rollout strategy—partnering with leading U.S. medical centers to validate, educate, and standardize CT:VQ™ as the benchmark for pulmonary imaging.

Expanding Horizons in Brazil with AstraZeneca

Beyond the U.S., 4DMedical’s partnership with AstraZeneca continues to gather momentum. Following initial success at Hospital Madre Teresa in Belo Horizonte, the Lung Health Screening Program will now expand to five new hospitals:

• Hospital 9 de Julho (H9J)
• Hospital Samaritano (HSH)
• Hospital Alvorada Moema (HAM)
• Hospital Santa Catarina (HSC)
• Unimed Joinville (UJ)
  
   

These additions create a balanced network of urban and regional centers across São Paulo and Santa Catarina, enabling scalability and improved data diversity.

The expanded program uses 4DMedical’s imaging analytics to detect early-stage lung diseases, including lung cancer, coronary artery calcification, and COPD. By combining the company’s advanced respiratory analytics with AstraZeneca’s public health reach, the initiative aims to accelerate early diagnosis and personalized treatment pathways for thousands of patients.

CEO Andreas Fouras: “Momentum Is Building”

Commenting on the dual milestones, 4DMedical’s Founder and CEO Andreas Fouras said:

“Our partnership with AstraZeneca continues to gain exceptional momentum. The expansion of the Brazilian Lung Health Screening Program to five additional hospitals, within just weeks of launch, demonstrates both the scalability of our platform and its growing importance in large-scale population health initiatives.

Stanford’s transition to a full commercial CT:VQ™ contract, less than two months after FDA clearance, represents a powerful validation of our go-to-market strategy. As a globally respected leader in clinical innovation, Stanford serves as an ideal anchor for our commercialisation approach—establishing a network of leading sites to accelerate awareness and adoption.”

Fouras added that the post-FDA clearance momentum is creating “a fundamental shift” for 4DMedical, with expectations for a strong FY26 ahead of the company’s appearance at the Radiological Society of North America (RSNA) in November.

4DMedical (ASX:4DX) is a global medical technology company revolutionizing lung diagnostics through advanced imaging and artificial intelligence. Its proprietary XV Technology® transforms standard CT scans into high-precision, functional lung insights—allowing clinicians to diagnose and monitor respiratory diseases earlier and more accurately.

The company’s software suite—delivered through a Software-as-a-Service (SaaS) model—includes the FDA-cleared XV Lung Ventilation Analysis Software (LVAS®), CT LVAS™, and the pioneering CT:VQ™ platform that integrates ventilation and perfusion analysis for unparalleled respiratory detail.

With recent momentum across the U.S. and Latin America, 4DMedical continues to strengthen its position as a frontrunner in digital health innovation and respiratory care.